Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 20;1(7):e000052.
doi: 10.1099/acmi.0.000052. eCollection 2019.

Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model

D B Huang  1   2 , S Noviello  1 , C G Gemmell  3
Affiliations

Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model

D B Huang et al. Access Microbiol. .

Abstract

Staphylococcus aureus is the most common non-gonococcal aetiology of septic arthritis. The efficacy of iclaprim against S. aureus LS-1, a clinical strain identified from a patient with septic arthritis, was studied in MF1 mice to evaluate the activity of iclaprim, which is in clinical development, in preventing joint infections. Iclaprim (2.5-80 mg kg- 1) administered as a single dose via the tail vein reduced the incidence of S. aureus septic arthritis and mortality in an experimental murine model of septic arthritis.

Keywords: iclaprim; murine model; septic arthritis.

PubMed Disclaimer

Conflict of interest statement

D. B. H. and S. N. are employed by and have stock ownership in Motif BioSciences, Inc. C. G. G. has received funds from numerous pharmaceutical companies for research and consultancy on antimicrobial compounds.

Similar articles

See all similar articles

References

    1. Combs K, Cox K. Clinical outcomes involving patients that develop septic arthritis with methicillin sensitive Staphylococcus aureus versus methicillin resistant Staphylococcus aureus. J Orthop. 2018;15:9–12. doi: 10.1016/j.jor.2017.11.007. - DOI - PMC - PubMed
    1. European Centre for Disease Prevention and Control Annual epidemiological report: antimicrobial resistance and healthcare-associated infections. 2014 www.ecdc.europa.eu on May 8, 2019.
    1. Centers for Disease Control and Prevention Methicillin-Resistant Staphylococcus aureus (MRSA) infections
    1. Huang DB, Dryden M, Iclaprim DM. Iclaprim, a dihydrofolate reductase inhibitor antibiotic in phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety. Future Microbiol. 2018;13:957–969. doi: 10.2217/fmb-2018-0061. - DOI - PubMed
    1. Huang DB, O'Riordan W, Overcash JS, Heller B, Amin F, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous Iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens: REVIVE-1. Clin Infect Dis. 2018;66:1222–1229. doi: 10.1093/cid/cix987. - DOI - PubMed

LinkOut - more resources